Activist Investor MAK Capital Demands Biologics Carve-Out, Faster Restructuring, and Board Seat at Evotec SE
Summary
Activist investor MAK Capital, holding a 7.0% stake in Evotec SE, has filed an amended Schedule 13D outlining specific demands including the carve-out and US listing of Just – Evotec Biologics, accelerated restructuring, and the appointment of a new board member.
Key Events
-
Activist Stake Confirmed
MAK Capital confirmed its 7.0% beneficial ownership in Evotec SE, making it one of the largest shareholders, following its initial Schedule 13D filing on March 30, 2026.
-
Demand for Just Biologics Carve-Out
MAK Capital urges Evotec to immediately begin the process of separating and pursuing a carve-out IPO of Just – Evotec Biologics on a U.S. exchange, believing it could be worth more than the entire current equity capitalization.
-
Call to Accelerate Restructuring
The activist investor criticized the slow pace of Evotec's "Horizon" transformation plan and demanded a compressed timeline for site consolidation and workforce actions, aiming for tangible operating improvements by the second half of 2026.
-
Proposed Board Appointment
MAK Capital proposed Dr. Wolfgang Hofmann for appointment to the Supervisory Board, citing his relevant experience, and stated readiness to exercise shareholder rights to nominate him if the company does not endorse the proposal.
Analysis
This amended Schedule 13D reveals the detailed agenda of activist investor MAK Capital, which has built a significant 7.0% stake in Evotec SE. The firm is pushing for a major strategic overhaul, including the separation and public listing of the high-growth Just – Evotec Biologics unit, which they believe is significantly undervalued within the current structure. Additionally, MAK Capital is demanding a faster pace for the company's "Horizon" transformation plan and is proposing its own candidate for the Supervisory Board, signaling a potential proxy contest if their proposals are not adopted. These demands, if implemented, could fundamentally alter Evotec's business structure and operational focus, potentially unlocking substantial shareholder value but also introducing near-term strategic uncertainty.
At the time of this filing, EVO was trading at $2.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $921.2M. The 52-week trading range was $2.31 to $4.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.